Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

d a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma. Micromet also has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Company (NYSE: PRGO ; TASE) today announced ... from the U.S. Food and Drug Administration (FDA) for ... gel 1.0%. FDA concluded that Perrigo,s testosterone product is ... substituted with the full expectation that it will produce ... 1% when used under the conditions specified in the ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Machine Health Monitoring Market by Product, Component, Application and ... report to their offering. ... market is expected to witness a moderate growth as ... have almost reached the saturation levels. The ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... Dec. 8, 2010 Reportlinker.com announces that a ... catalogue: Astellas Pharma Inc.: PharmaVitae ... IntroductionThis analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... 8, 2010 Healthpoint today announced that the U.S. ... commercial supplies of Collagenase SANTYL® Ointment, a biologic enzymatic ... Sterile & Specialty Products facility in Lakewood, New Jersey. ... the brand. "The approval of this second ...
Cached Medicine Technology:Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile 2FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment 2
(Date:7/24/2014)... Doheny HealthDay Reporter THURSDAY, ... often don,t view their kids as unhealthy or recognize the ... new study. The children of the families surveyed for ... Hasbro Children,s Hospital in Providence, R.I. "A third categorized ... researcher Dr. Kyung Rhee, now an assistant professor of pediatrics ...
(Date:7/24/2014)... have found a way to delay or even prevent ... with the anti-aging protein Klotho can prevent neuron death ... glutamate. These findings currently appear in the Journal ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people over the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 News ... that it has achieved certification for compliance with ... and verified by the DoD Information Assurance Certification ... Neutral Archive, identified within the DoD as the ... to Operate designation from the U.S. Army Medical ...
(Date:7/24/2014)... positive outcomes experience paradoxical feelings of pleasure and ... of the brain, according to research led by ... Princeton Neuroscience Institute at Princeton University. , ... of more than 300 products using an auction-like ... products with different or similar values and were ...
(Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... LDG ) today reported preliminary total retail drug,store sales for the five-week and nine-week periods ended April 3, 2008., , ... Periods ended April 3, 2008, ... Month Quarter to Date (Dollars in millions) ... (9 weeks), Total retail drug store sales $474 ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
... consequences of misuse , , THURSDAY, April 10 (HealthDay News) ... abuse of powerful narcotic painkillers such as Oxycontin or ... testing --- before dispensing the medications to patients, new ... medical staff were also part of the procedures used ...
... Pennsylvania School of Medicine have discovered that a protein ... heart muscle protein called actin. Whats more, Lmod directs ... of the heart. The findings appear in this weeks ... Lmod when we began this study, says lead author ...
... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that it ... maturities of the,Bonds. The tender offer was extended on ... 9, 2008 at 5:00 pm, New York City time. ... terminated is applicable to,the following: for the Series 1985C ...
... Held on Saturday, April 12th at the ... Helen Mills Theatre in NYC, NEW ... performing a benefit concert on Saturday,April 12th at the Helen Mills Theatre ... This One,s Personal: A,Concert to Stop ACD," is being hosted by the ...
Cached Medicine News:Health News:Longs Reports Preliminary March Retail Drug Store Sales 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:User Registry May Help Docs Stem Painkiller Abuse 2Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: